Auris Medical Holding AG Company Profile (NASDAQ:EARS)

Auris Medical Holding AG trades on the NASDAQ under the ticker symbol "EARS."

Auris Medical Holding AG (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.08. View Auris Medical Holding AG's Earnings History.

5 equities research analysts have issued 1 year target prices for Auris Medical Holding AG's shares. Their predictions range from $4.00 to $12.00. On average, they anticipate Auris Medical Holding AG's share price to reach $6.83 in the next year. View Analyst Ratings for Auris Medical Holding AG.

Here are some recent quotes from research analysts about Auris Medical Holding AG stock:

• 1. Needham & Company LLC analysts commented, "EARS reported 4Q16 financials and update its three ongoing development programs. The next key data catalyst for EARS will be ph 3 HEALOS results for AM-111 (hearing loss) in 3Q17. The study, which should complete enrollment in 2Q17, is the first of two AM-111 pivotal studies in hearing loss. The Keyzilen program will first report results from the open-label studies (AMPACT-1 and 2) in 2Q17 while the recently modified TACCT3 study is on track to have top-line results in 1Q18. EARS plans to evaluate AM-125 (Meniere's disease/vertigo) in an additional ph 1 trial (initiating in 2H17) prior to discussing a regulatory pathway with regulatory authorities. The current EARS market valuation appears to place minimal to no value on any of the ongoing clinical programs.We maintain our Buy rating and adjust our $PT to $4 (from $5)." (3/14/2017)
• 2. According to Zacks Investment Research, "Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. " (1/10/2017)

Auris Medical Holding AG saw a increase in short interest in April. As of April 28th, there was short interest totalling 1,075,288 shares, an increase of 15.4% from the April 13th total of 932,128 shares. Based on an average trading volume of 174,449 shares, the short-interest ratio is currently 6.2 days.

Some companies that are related to Auris Medical Holding AG include Bellerophon Therapeutics (BLPH), Cleveland BioLabs (CBLI), Biopharmx Corp (BPMX), Trillium Therapeutics (TRIL), Burcon NutraScience Corp (BUR), Nivalis Therapeutics (NVLS), Chiasma (CHMA), Histogenics Corp (HSGX), Threshold Pharmaceuticals (THLD), KaloBios Pharmaceuticals (KBIO), Can Fite Biopharma Ltd (CANF), Alcobra Ltd (ADHD), Dimension Therapeutics (DMTX), Viking Therapeutics (VKTX), Catabasis Pharmaceuticals (CATB), Mirna Therapeutics (MIRN), Aldeyra Therapeutics (ALDX) and Ocera Therapeutics (OCRX).

Auris Medical Holding AG's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SOFINNOVA VENTURE PARTNERS VIII, L.P. (20.20%), Sofinnova Management VIII L.L.C. (22.77%), Bellevue Group AG (6.32%), Tekla Capital Management LLC (2.26%), Perceptive Advisors LLC (1.17%) and Morgan Stanley (0.44%). View Institutional Ownership Trends for Auris Medical Holding AG.

Auris Medical Holding AG's stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Management VIII L.L.C., Perceptive Advisors LLC, Morgan Stanley and Sabby Management LLC. View Insider Buying and Selling for Auris Medical Holding AG.

Shares of Auris Medical Holding AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Auris Medical Holding AG stock can currently be purchased for approximately $0.67.